Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

7.290 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
From Kezar Life Science
Via Business Wire
News headline image
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Wells Fargo Beefs Up Kezar Life Price Target - Read Why ↗
 
Via Benzinga
News headline image
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Stock Shows Rising Market Leadership: Earns 81 RS Rating ↗
The Relative Strength (RS) Rating for Kezar Life Sciences stock jumped into a new percentile Friday, with a rise from 78 to 81. 
Via Investor's Business Daily
News headline image
Kezar Life Sciences to Present at the William Blair Biotech Focus Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences (KZR) Stock Soars on Lupus Trial Results ↗
KZR stock is soaring today on news that Kezar Life Sciences' Lupus treatment showed positive results in a clinical trial. 
Via InvestorPlace
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
The Week In Charts: How To Make Money While Waiting For Core Trend Trades ↗
The real money is in the longer-term core trend trades. However, sometimes those opportunities can be few and far between. This is especially true in a bear market. 
Via Talk Markets
News headline image
Biotech ETF Tops in June: 5 Stocks That Outperform ↗
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%. 
Via Talk Markets
News headline image
Short Volatility Alert: Kezar Life Sciences, Inc. ↗
On Tuesday, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) experienced volatile short activity. After the activity, the stock price went up +43.43% to $8.29. The overall sentiment for KZR has been... 
Via Benzinga
News headline image
InflaRx Climbs More Than 40%, Here's 58 Biggest Movers From Yesterday ↗
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) shares climbed 89.8% to close at $2.41 on Tuesday. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
Dow Dips Over 400 Points; Crude Oil Rises 2% ↗
U.S. stocks turned sharply lower toward the end of trading, with the Dow Jones dropping more than 400 points on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Nasdaq Turns Lower; Kezar Life Sciences Shares Jump ↗
U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday. 
Via Benzinga
News headline image
Why Is Ceragon Networks Surging By 19%? 41 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Agile Therapeutics, Inc. (NASDAQ: AGRX) jumped 88.9% to $2.3986. Agile Therapeutics shares climbed over 10% on Monday amid the Supreme Court overturning Roe V Wade. 
Via Benzinga
News headline image
Occidental Petroleum (OXY) Stock Gets Boost From Yet Another Buffett Buy ↗
Occidental Petroleum (OXY) stock is rising on Tuesday after Warren Buffett's Berkshire Hathaway increased its stake in the company. 
Via InvestorPlace
News headline image
Markets Open Higher; US Goods Gap Narrows To $104.3B In May ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining over 350 points on Tuesday. 
Via Benzinga
News headline image
Why Kezar Life Sciences Stock Is Soaring Today ↗
Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging Tuesday after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning! It's time for another dive into the biggest pre-market stock movers as we go over the news for Tuesday morning! 
Via InvestorPlace
News headline image
Why Is Kezar Life Sciences Surging By 78%? 25 Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical trial evaluating... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Kezar Life Shares Shoot Higher After Positive Results From Mid-Stage Study Of Kidney Disease Candidate ↗
Kezar Life Sciences, Inc. (NASDAQ: KZR) reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib in patients with active lupus nephritis (LN). 
Via Benzinga
News headline image
After-Hours Action: Why Kezar Life Sciences Stock Is Soaring ↗
Kezar Life Sciences Inc (NASDAQ: KZR) shares are surging in Monday's after-hours session after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib. 
Via Benzinga
News headline image
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Billionaire Israel Englander Is Betting Big on These 5 Stocks ↗
Millennium Management's Israel Englander is in focus after the billionaire's fund purchased several stocks this month. 
Via InvestorPlace
News headline image
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Kezar Life Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.